Scrip“We’ve seen some tremendous acceleration in science over the past few years and that science is the driving force behind new medicines. The fundamental need for these new medicines is the underpinning
ScripAriBio Co., Ltd. is set to become the first South Korean pharma firm to begin a global Phase III clinical development program for a novel drug for Alzheimer’s disease (AD), following an IND approval